%0 Journal Article
%A Santander Ballestín, Sonia
%A Abadía Labena, María
%A Avedillo-Salas, Ana
%A Marco Continente, Cristina
%A Arribas Blázquez, Marina
%A Luesma Bartolomé, María José
%T Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
%D 2025
%@ 2072-6694
%U https://hdl.handle.net/20.500.14352/118832
%X Background and Objectives: Breast cancer is the most common malignant neoplasm worldwide and the most prevalent one among women. It represents the leading cause of cancer-related death among females. Cyclin-dependent kinase 4 and 6 inhibitors disrupt the cell cycle, inducing cellular senescence and, ultimately, apoptosis. Consequently, they have become a novel type of adjuvant therapy for the treatment of advanced or metastatic breast cancer characterised by positive hormone receptors and human epidermal growth factor receptor 2 (HER-2) negative.Methods: A systematic review was conducted, analysing the available literature on cyclin-dependent kinase 4 and 6 inhibitors published over the last five years. The aim was to evaluate the efficacy and safety of adding these drugs to the standard endocrine therapy for this pathology.Results: The combination of cyclin-dependent kinase 4 and 6 inhibitors with endocrine therapy was shown to improve progression-free survival, overall survival, and chemotherapy-free intervals in patients who received this combination therapy.Conclusions: The addition of CDK4/6 inhibitors to endocrine therapy in the treatment of advanced or metastatic breast cancer with positive hormone receptors and HER-2 negative significantly improved PFS, median survival, and chemotherapy-free intervals compared with the use of hormonal treatments alone or in combination with a placebo. Currently, CDK4/6 inhibitors are becoming established as a new standard treatment for this pathology, offering lower toxicity than chemotherapy. However, it is necessary to deeply investigate the mechanisms of treatment resistance and develop effective therapies to overcome them.
%X Simple Summary:Breast cancer is the most common malignant neoplasm worldwide and the most prevalent one among women. Cyclin-dependent kinase 4 and 6 inhibitors have become a novel form of adjuvant therapy for the treatment of advanced or metastatic breast cancer characterised by positive hormone receptors and human epidermal growth factor receptor 2 (HER-2) negative. These inhibitors are considered a new standard treatment for this pathology, offering lower toxicity than chemotherapy.
%~